Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒‒ Expects ...

Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarterPreliminary ending 2025 cash and cash ...

Patients with ABI require prolonged mechanical ventilation and have a substantially higher risk for VAP due to impaired airway protection and injury-related immune dysfunction. However, routine use of ...

Hemophilia A and B involve deficiencies in coagulation factors VIII and IX, with traditional treatments requiring frequent infusions. Nonfactor therapies, including Hemlibra and rebalancing agents, ...

A study suggests twice-yearly Yeztugo offers HIV prevention without adversely affecting gender-affirming care.

Mrs Gifty Addo-Tetebo, Eastern Regional Coordinator for STI /HIV and AIDS at the Regional Health Directorate, has entreated ...

Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field studyExpect to ...

New York has passed several new laws taking effect in January and February, including requirements for doctors and hospitals ...

Surgical antimicrobial prophylaxis using non-beta‑lactams administered before major surgery was independently associated with a significantly higher risk for surgical site infection than conventional ...

On July 25, The European Medicines Agency (EMA)’s advisory committee recommended Gilead Sciences’ Lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents. Any ...

The recent deaths of three young girls following rabies, in separate incidents in Pathanamthitta, Malappuram and Kollam, in spite of post-exposure prophylaxis with anti-rabies vaccine as well as ...

Prevention doesn’t come easy. The bar is high. The decision to act medically because an untoward outcome could occur means creating intervention side-effect risk that’s otherwise absent. Large patient ...